Clinigen Group Given New GBX 469 Price Target at Investec (CLIN)
Investment analysts at Investec hoisted their price target on shares of Clinigen Group (LON:CLIN) from GBX 313 ($5.06) to GBX 469 ($7.58) in a note issued to investors on Thursday, Stock Ratings News reports. The firm currently has a “hold” rating on the stock. Investec’s price target suggests a potential downside of 0.64% from the stock’s previous close.
Separately, analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Clinigen Group in a research note to investors on Wednesday, September 25th. They now have a GBX 485 ($7.84) price target on the stock.
Shares of Clinigen Group (LON:CLIN) traded down 0.63% during mid-day trading on Thursday, hitting GBX 472.00. The stock had a trading volume of 83,278 shares. Clinigen Group has a 52-week low of GBX 195.00 and a 52-week high of GBX 494.25. The stock’s 50-day moving average is GBX 414.9 and its 200-day moving average is GBX 331.0.
Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.